Research programme: Herpes simplex virus antimicrobial peptoids for herpes labialis - Maxwell Biosciences
Alternative Names: CLAROMER™; MXB-001; MXB-002Latest Information Update: 08 Apr 2021
Price :
$50 *
At a glance
- Originator Maxwell Biosciences
- Class Antimicrobial cationic peptides; Antivirals; Peptoids; Small molecules
- Mechanism of Action Viral envelope protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Herpes labialis
Most Recent Events
- 08 Apr 2021 Maxwell Biosciences has patent protection for composition of matter portfolio for its anti-infectives program (Maxwell Biosciences pipeline, April 2021)
- 08 Apr 2021 Maxwell Biosciences has patent protection for virucidal peptoid class in USA (Maxwell Biosciences pipeline, April 2021).
- 05 Apr 2021 Preclinical trials in Herpes labialis in USA (Topical) (Maxwell Biosciences pipeline, April 2021)